concept

LECANEMAB

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about LECANEMAB: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

108Connections

0Hypotheses

1Analyses

26Outgoing

34Incoming

No summary available yet. View on Wiki →

💡 Concept Info

Name	LECANEMAB
Summary	Phase 2b clinical trial of BAN2401 (lecanemab) in early Alzheimer's disease with innovative Bayesian adaptive design
Key Genes/Proteins	AMYLOID, APP
Related Diseases	AMYLOID PLAQUES, ALZHEIMER'S DISEASE, ALZHEIMER, DEMENTIA

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    LECANEMAB["LECANEMAB"]
    LECANEMAB -->|"treats"| Cognitive_Decline["Cognitive Decline"]
    LECANEMAB -->|"targets"| Amyloid_Beta["Amyloid Beta"]
    LECANEMAB -->|"targets"| Amyloid__["Amyloid-beta"]
    LECANEMAB -->|"targets"| AMYLOID_BETA["AMYLOID-BETA"]
    LECANEMAB -->|"treats"| Early_Stage_Alzheimer_s_Diseas["Early-Stage Alzheimer's Disease"]
    LECANEMAB -->|"targets"| Brain_Amyloid_Pathology["Brain Amyloid Pathology"]
    LECANEMAB -->|"targets"| Amyloid_Pathology["Amyloid Pathology"]
    Anticoagulation["Anticoagulation"] -->|"interacts"| LECANEMAB
    DONANEMAB["DONANEMAB"] -->|"target for"| LECANEMAB
    ADUCANUMAB["ADUCANUMAB"] -->|"target for"| LECANEMAB
    Amyloid["Amyloid"] -->|"interacts"| LECANEMAB
    AMYLOID["AMYLOID"] -->|"target for"| LECANEMAB
    ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"] -->|"target for"| LECANEMAB

Outgoing (71)

Target	Relation	Type	Str
AMYLOID PLAQUES	causes	phenotype	0.65
AMYLOID	regulates	protein	0.65
ALZHEIMER'S DISEASE	interacts_with	disease	0.65
ALZHEIMER'S DISEASE	activates	disease	0.65
NEURON	synergizes_with	cell_type	0.60
NEURON	stabilizes	cell_type	0.60
NEURON	associated_with	cell_type	0.50
APP	associated_with	gene	0.50
TAU	associated_with	protein	0.50
AGING	associated_with	phenotype	0.50
AUTOPHAGY	associated_with	phenotype	0.50
TH	associated_with	gene	0.50
TREM2	associated_with	gene	0.50
MICROGLIA	associated_with	cell_type	0.50
BACE1	associated_with	gene	0.50
BDNF	associated_with	gene	0.50
NGF	associated_with	gene	0.50
ASTROCYTE	associated_with	cell_type	0.50
CSF	associated_with	phenotype	0.50
DONANEMAB	associated_with	drug	0.45
AMYLOID	associated_with	protein	0.45
ALZHEIMER	associated_with	disease	0.45
DEMENTIA	associated_with	disease	0.45
APOE	associated_with	gene	0.45
APOE4	associated_with	gene	0.45
ad_clinical_trial_failures:lecanemab	data_in	dataset_row	0.00

Incoming (37)

Source	Relation	Type	Str
DONANEMAB	therapeutic_target	drug	0.80
ADUCANUMAB	therapeutic_target	drug	0.80
AMYLOID	therapeutic_target	protein	0.65
ALZHEIMER	treats	disease	0.65
ALZHEIMER'S DISEASE	treats	disease	0.65
DEMENTIA	treats	disease	0.65
ADUCANUMAB	targets	drug	0.65
ALZHEIMER'S DISEASE	therapeutic_target	disease	0.50
MITOCHONDRIAL DYSFUNCTION	associated_with	phenotype	0.50
PROTEIN AGGREGATION	associated_with	phenotype	0.50
PROTEOSTASIS	associated_with	phenotype	0.50
NEUROINFLAMMATION	associated_with	phenotype	0.50
AMYLOID-BETA	associated_with	protein	0.50
NEURODEGENERATION	associated_with	phenotype	0.50
INFLAMMATION	associated_with	phenotype	0.50
ADUCANUMAB	associated_with	drug	0.45
COGNITIVE DECLINE	associated_with	phenotype	0.45
DONANEMAB	associated_with	drug	0.45
AMYLOID	associated_with	protein	0.45
ALZHEIMER	associated_with	disease	0.45
DEMENTIA	associated_with	disease	0.45
APOE	associated_with	gene	0.45
AMYLOID PLAQUES	associated_with	phenotype	0.45
MULTIPLE SCLEROSIS	associated_with	disease	0.45
GANTENERUMAB	associated_with	drug	0.45
SOLANEZUMAB	associated_with	drug	0.45
CRENEZUMAB	associated_with	drug	0.45
CEREBRAL AMYLOID ANGIOPATHY	associated_with	disease	0.45
DONANEMAB	implicated_in	drug	0.35
AMYLOID	implicated_in	protein	0.35
ALZHEIMER'S DISEASE	associated_with	disease	0.35
DEMENTIA	therapeutic_target	disease	0.35
APOE	therapeutic_target	gene	0.35
ad_clinical_trial_failures:lecanemab	data_in	dataset_row	0.00

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (1)

Scientific analyses that reference this entity

Blood-brain barrier transport mechanisms for antibody therapeutics

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.566

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

LECANEMAB

Understanding Entity Pages

Wiki Pages (21)

Ban2401 Phase 2b Trial (201 Study)

nhp-validation-animal-model

Therapeutics

Alzheimer's Disease

p-tau-217

CBS/PSP Clinical Trials Guide

APOC4 — Apolipoprotein C-IV

TREM2 Microglial Signaling Pathway in Neurodegeneration

University of Heidelberg

dendritic-spines

blood-brain-barrier

dimethyl-fumarate-nrf2-ad-nct06850597

A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

PMN310 Anti-Amyloid for AD (NCT06750432)

Clinical Trials Dashboard

Amyloid Cascade Pathway

Cerebrospinal Fluid (CSF) Biomarkers Overview

rankings

Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516)

Gene-Mechanism-Therapy Causal Chains